aiwell ProteoSIGN Platform

From Japanese proteomics innovation
to a U.S. biomarker discovery ecosystem

Texas Hands-on Support Program
16 Sep 2026

Who we are?

A Startup from
Institute of SCIENCE TOKYO
(Tokyo Institute of Technology)

aiwell Inc
Established in
2018

aiwell
Beyond The Gene



2018 ~2022



Office in Tokyo



Lab in Kawasaki

Main Service:
Proteomics Solution











Company vision- Toward a society of sustained health


Detect signs of disease or injury while still healthy

No noticeable symptoms
Prevent illnesses or injuries in advance through medication, instructions, or interventions



Provision of protein samples

Vital
&




Creation of proteomics images

Feedback for users

Menopause
Cancer
Depression
Metabolic syndrome
etc

AI

DB





lifestyle Improvement



Offering health insights



Early medical intervention

Our proprietary AI, trained on proteomics images of diseases and disorders, assesses health conditions

© aiwell Inc. ALL RIGHTS RESERVED.

AI-powered high-precision 2D electrophoresis image analysis + Mass spectrometry " ProteoSIGN "

Achieving high accuracy, low cost, and ultra-rapid biomarker discovery: the only seamless, integrated platform

[Technical breakdown of ProteoSIGN]

- **Separates proteins whole (non-degraded) and covers all aspects of AIP**
- **AI identifies "biologically unique spots" in images within weeks**

LC-MS: Precisely measures only the specific locations identified by Integrated Proteomics Analysis


【Analysis Example】
Searching for indicators (biomarkers) of a disease

Step 1:
Obtain images from blood samples

Step 2:
Compare images using AI
Patient images

Step 3:
Identify differences (spot locations)
Search for biomarker (BM) candidates

Step 4:
Mass spectrometry analysis (specific locations)
Identification of biomarker candidates




Instead of scanning all data with mass spectrometry from the start, IPA uses AI to pinpoint suspicious spots first, then confirms only targeted areas with world-standard mass spectrometry — combining speed with high accuracy.

© aiwell Inc. ALL RIGHTS RESERVED.

Why Texas? Opportunities We See in Texas

Three complementary ecosystems — with Houston as the clinical entry point



Houston **Clinical collaborations**

Texas Medical Center ecosystem; access to hospitals, research institutions and clinically relevant partnerships.

Austin **Technology ecosystem**

AI talent, health-tech innovation and technology partnerships.

Dallas **Business connectivity**

Strong transport links and a potential hub for broader U.S. access.

© aiwell Inc. ALL RIGHTS RESERVED.